Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
Open Access
- 2 April 2020
- Vol. 12 (4), 869
- https://doi.org/10.3390/cancers12040869
Abstract
High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses—of more than 10-fold lower than previously reported for other cancers—significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.Keywords
Funding Information
- Mater Foundation (NA)
This publication has 49 references indexed in Scilit:
- Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review)Oncology Letters, 2013
- New perspectives on molecular targeted therapy in ovarian clear cell carcinomaBritish Journal of Cancer, 2013
- Glycogen and its metabolism: some new developments and old themesBiochemical Journal, 2012
- Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesisPathology, 2011
- Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinomaGynecologic Oncology, 2011
- Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010Gynecologic Oncology, 2011
- Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignanciesThe Prostate, 2010
- Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined platinum and 2-deoxy-d-glucose treatmentMolecular Cancer Therapeutics, 2009
- Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylationMolecular Cancer Therapeutics, 2007
- Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?The Oncologist, 2006